Weight-management medication: oral vs injection, cost and follow-up

A useful weight-management program should help you understand the clinical decision, the daily routine and the full cost before you pay. Medication can be one part of care, but a request does not guarantee that medication, testing or virtual care is appropriate for you.

1. Oral or injectable: start with the product, not only the format

Two practical formats may come up in a clinician discussion: oral tablets and injections. They are not interchangeable. The indication, dosing instructions, contraindications, evidence and availability depend on the exact product. A clinician must review your health history, current medications, goals and risks before deciding whether any option is appropriate.

If an oral semaglutide product is discussed

The current Canadian Rybelsus monograph says it is taken once daily on an empty stomach, at least 30 minutes before the first food, drink or other oral medication of the day, with no more than 120 mL of water. Those are product-specific instructions, not a general rule for every oral weight-management medication. Follow only the instructions for the product actually prescribed to you.

If a weekly injectable semaglutide product is discussed

The current Canadian Wegovy monograph describes a subcutaneous injection used once weekly, preferably on the same day each week. Health Canada also authorized a first generic semaglutide injection for chronic weight management in June 2026. A weekly schedule can be simpler for some people, but injection technique, storage, side effects, supply and product-specific instructions still need to be reviewed.

• Ask which exact product and indication the clinician is considering.
• Ask how the routine fits your mornings, meals, other oral medications, travel and storage needs.
• Ask what side effects or warning signs should lead you to contact a clinician or seek in-person care.
• Never start, stop, combine or change a dose from an online article.

2. Confirm pharmacy stock and the real monthly price

Medication is dispensed and billed separately by the pharmacy. Stock can change by product, strength, package and location. Before committing to a plan, ask the pharmacy whether it can supply the exact product and strength, whether a refill delay is expected, and whether an authorized generic or another product is available. Do not switch products without the clinician and pharmacist reviewing the change.

For budgeting only, patients may encounter monthly cash costs from roughly CAD $150 to CAD $400 or more. That range is not a quote or a promise. The exact amount can change with the product, dose, package, generic availability, pharmacy, province, insurance and public coverage. For context, a 2025 CDA-AMC review recorded a sponsor-submitted price of $388.64 for one Wegovy multi-use pen containing four doses; retail and out-of-pocket prices can differ.

• What is the pharmacy cash price for the exact product, strength and package today?
• Is it in stock, and what happens if the next strength is unavailable?
• Is an authorized generic available and appropriate for this indication?
• What will insurance or a public plan cover, and what remains out of pocket?
• Are needles, supplies, dispensing fees or laboratory fees separate?

3. What the initial MedVibe assessment includes

MedVibe’s initial weight-management clinical assessment is CAD $150 and tax-exempt, with no subscription required. A clinician reviews the information you provide, including relevant health history, current medications, goals and practical constraints, and decides which next steps—if any—are appropriate for virtual care.

When clinically indicated, the clinician may provide a laboratory requisition during the assessment. A requisition is not automatic or guaranteed. Laboratory and other third-party fees, if any, are separate. Some situations need an in-person exam, another clinician or a different care setting before medication or follow-up can be considered.

• Bring your current medication and supplement list, allergies and relevant diagnoses.
• Share recent measurements or laboratory results if you already have them.
• Explain prior weight-management treatments, benefits, side effects and reasons for stopping.
• Prepare questions about pregnancy plans, other conditions, interactions and urgent symptoms when relevant.

4. What can be reviewed on day 21

For eligible completed initial care, MedVibe has a separate clinician-gated follow-up that can be offered only on day 21 after the initial consultation. It is a 15-minute, CAD $75 tax-exempt visit. It is not included in the initial $150 assessment, not automatic, and not guaranteed; a suitable care record, clinician approval and an available time are required.

At that follow-up, the clinician can review how the first 21 days went, including medication use, tolerance, early response, questions and any laboratory results that are already available. The clinician then decides whether continuing the plan, changing the dose or product, arranging more testing, or moving care in person is appropriate. No adjustment is automatic, and some products are intentionally titrated over longer product-specific schedules.

5. Seven questions to ask before you pay

• Who performs the assessment, and in which provinces can that clinician care for patients?
• Is the product being discussed authorized for this indication, or would the use be off-label?
• What is included in the initial fee, and which medication, laboratory, pharmacy and follow-up costs are separate?
• Has a pharmacy confirmed the exact product, strength, stock and price?
• How will oral or injectable instructions fit my routine and current medicines?
• When would laboratory testing or an in-person assessment be needed?
• What follow-up is clinically appropriate, when does it occur, and what happens if I need help earlier?

A trustworthy program should answer these questions without promising a prescription, a specific product, uninterrupted stock, an exact price or a weight-loss result. The goal of the first visit is a safe clinical decision and a clear next step—not a preselected medication.